Skip to main content
Top
Published in: Virology Journal 1/2019

Open Access 01-12-2019 | Hepatitis B | Research

Tumor necrosis factor-α-induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection

Authors: Yi Liu, Jia Jin, Jian Ji, Xi-Mei Gao, Yu-Chen Fan

Published in: Virology Journal | Issue 1/2019

Login to get access

Abstract

Background

Tumor necrosis factor-alpha-induced protein 8-like 2 (TIPE2) is a novel target and molecule in the negative regulation of immune homeostasis. The present study aimed to investigate the dynamic expression of TIPE2 mRNA during the progression of chronic hepatitis B virus (HBV) infection.

Methods

A total of 193 patients with chronic HBV infection were retrospectively recruited into this cross-sectional study, including 97 patients with chronic hepatitis B (CHB), 55 with liver cirrhosis and 41 with HBV-related hepatocellular carcinoma (HCC). TIPE2 mRNA was determined using real-time quantitative polymerase chain reaction.

Results

The expression of TIPE2 levels in patients with HCC was significantly decreased compared with expression in patients with liver cirrhosis, CHB and healthy controls (P < 0.05); meanwhile, the TIPE2 mRNA levels in patients with CHB and liver cirrhosis were significantly increased compared with levels in healthy controls (P < 0.01). In liver cirrhosis, the TIPE2 mRNA level in the decompensated state was significantly higher than that in the compensated state (P < 0.05). In HCC patients, TIPE2 mRNA was significantly associated with venous invasion, tumor size and tumor node metastasis stage. Furthermore, the optimal cutoff of 0.78 for the level of TIPE2 mRNA has a sensitivity of 97.56% and a specificity of 88.16% for discriminating HCC from patients with CHB and liver cirrhosis.

Conclusions

TIPE2 mRNA was associated with various stages of chronic HBV infection, ranging from CHB to liver cirrhosis and HCC. Furthermore, TIPE2 mRNA with an optional cutoff value of 0.78 might serve as a promising biomarker to discriminate HBV-associated HCC from CHB and LC patients.
Literature
1.
go back to reference Scaglione SJ, Lok ASF. Effectiveness of Hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360.CrossRef Scaglione SJ, Lok ASF. Effectiveness of Hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360.CrossRef
2.
go back to reference Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.CrossRef Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.CrossRef
3.
go back to reference Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594–604.CrossRef Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594–604.CrossRef
4.
go back to reference Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52–9.CrossRef Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52–9.CrossRef
5.
go back to reference Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRef Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRef
6.
go back to reference Ji J, Zhang YY, Fan YC. TIPE2 as a potential therapeutic target in chronic viral hepatitis. Expert Opin Ther Targets. 2019;23:485–93.CrossRef Ji J, Zhang YY, Fan YC. TIPE2 as a potential therapeutic target in chronic viral hepatitis. Expert Opin Ther Targets. 2019;23:485–93.CrossRef
7.
go back to reference Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133:415–26.CrossRef Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133:415–26.CrossRef
8.
go back to reference Zhang X, Wang J, Fan C, Li H, Sun H, Gong S, Chen YH, Shi Y. Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol. 2009;16:89–90.CrossRef Zhang X, Wang J, Fan C, Li H, Sun H, Gong S, Chen YH, Shi Y. Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol. 2009;16:89–90.CrossRef
9.
go back to reference Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol. 2012;189:2768–73.CrossRef Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol. 2012;189:2768–73.CrossRef
10.
go back to reference Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, Ruan Q, Guo W, Chen YH. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A. 2012;109:15413–8.CrossRef Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, Ruan Q, Guo W, Chen YH. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A. 2012;109:15413–8.CrossRef
11.
go back to reference Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell. 2012;45:610–8.CrossRef Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell. 2012;45:610–8.CrossRef
12.
go back to reference Xi WJ, Hu YJ, Liu YG, Zhang J, Wang L, Lou YW, Qu ZH, Cui J, Zhang GZ, Liang XH, et al. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol. 2011;48:1203–8.CrossRef Xi WJ, Hu YJ, Liu YG, Zhang J, Wang L, Lou YW, Qu ZH, Cui J, Zhang GZ, Liang XH, et al. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol. 2011;48:1203–8.CrossRef
13.
go back to reference Kong L, Liu K, Zhang YZ, Jin M, Wu BR, Wang WZ, Li W, Nan YM, Chen YH. Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C. Hepatol Int. 2013;7:844–9.CrossRef Kong L, Liu K, Zhang YZ, Jin M, Wu BR, Wang WZ, Li W, Nan YM, Chen YH. Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C. Hepatol Int. 2013;7:844–9.CrossRef
14.
go back to reference Li D, Song LJ, Fan YC, Li X, Li YJ, Chen J, Zhu FL, Guo C, Shi YY, Zhang LN. Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol. 2009;133:422–7.CrossRef Li D, Song LJ, Fan YC, Li X, Li YJ, Chen J, Zhu FL, Guo C, Shi YY, Zhang LN. Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol. 2009;133:422–7.CrossRef
15.
go back to reference Lou YW, Sun HH, Morrissey S, Porturas T, Liu SX, Hua XX, Chen YHH. Critical roles of TIPE2 protein in murine experimental colitis. J Immunol. 2014;193:1064–70.CrossRef Lou YW, Sun HH, Morrissey S, Porturas T, Liu SX, Hua XX, Chen YHH. Critical roles of TIPE2 protein in murine experimental colitis. J Immunol. 2014;193:1064–70.CrossRef
16.
go back to reference Zhang Y, Wei XB, Liu LX, Liu SX, Wang ZY, Zhang B, Fan BX, Yang F, Huang SY, Jiang F, et al. TIPE2, a novel regulator of immunity, protects against experimental stroke. J Biol Chem. 2012;287:32546–55.CrossRef Zhang Y, Wei XB, Liu LX, Liu SX, Wang ZY, Zhang B, Fan BX, Yang F, Huang SY, Jiang F, et al. TIPE2, a novel regulator of immunity, protects against experimental stroke. J Biol Chem. 2012;287:32546–55.CrossRef
17.
go back to reference Zhang SY, Zhang Y, Wei XB, Zhen JH, Wang ZY, Li MY, Miao W, Ding H, Du PC, Zhang WC, et al. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta Mol basis Dis. 2010;1802:1078–86.CrossRef Zhang SY, Zhang Y, Wei XB, Zhen JH, Wang ZY, Li MY, Miao W, Ding H, Du PC, Zhang WC, et al. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta Mol basis Dis. 2010;1802:1078–86.CrossRef
18.
go back to reference Zhao Q, Zhao M, Dong T, Zhou C, Peng Y, Zhou X, Fan B, Ma W, Han M, Liu S. Tumor necrosis factor-alpha-induced Protein-8 Like-2 (TIPE2) Upregulates p27 to decrease Gastic Cancer cell proliferation. J Cell Biochem. 2015;116:1121–9.CrossRef Zhao Q, Zhao M, Dong T, Zhou C, Peng Y, Zhou X, Fan B, Ma W, Han M, Liu S. Tumor necrosis factor-alpha-induced Protein-8 Like-2 (TIPE2) Upregulates p27 to decrease Gastic Cancer cell proliferation. J Cell Biochem. 2015;116:1121–9.CrossRef
19.
go back to reference Zhang G, Zhao L, Wang Y, Shao J, Cui J, Lou Y, Geng M, Zhang N, Chen YH, Liu S. TIPE2 protein prevents injury-induced restenosis in mice. Biochim Biophys Acta. 2015;1852:1574–84.CrossRef Zhang G, Zhao L, Wang Y, Shao J, Cui J, Lou Y, Geng M, Zhang N, Chen YH, Liu S. TIPE2 protein prevents injury-induced restenosis in mice. Biochim Biophys Acta. 2015;1852:1574–84.CrossRef
20.
go back to reference Lou Y, Liu S, Zhang C, Zhang G, Li J, Ni M, An G, Dong M, Liu X, Zhu F, et al. Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J Immunol. 2013;191:4849–57.CrossRef Lou Y, Liu S, Zhang C, Zhang G, Li J, Ni M, An G, Dong M, Liu X, Zhu F, et al. Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J Immunol. 2013;191:4849–57.CrossRef
21.
go back to reference Cao X, Zhang L, Shi Y, Sun Y, Dai S, Guo C, Zhu F, Wang Q, Wang J, Wang X, et al. Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1. Mol Cancer. 2013;12:149.CrossRef Cao X, Zhang L, Shi Y, Sun Y, Dai S, Guo C, Zhu F, Wang Q, Wang J, Wang X, et al. Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1. Mol Cancer. 2013;12:149.CrossRef
22.
go back to reference Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRef Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRef
23.
go back to reference Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal Varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997–1009 e1005.CrossRef Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal Varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997–1009 e1005.CrossRef
24.
go back to reference Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRef Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRef
25.
go back to reference Hellmann F, Verdi M, Schlemper BR Jr, Caponi S. 50th anniversary of the declaration of Helsinki: the double standard was introduced. Arch Med Res. 2014;45:600–1.CrossRef Hellmann F, Verdi M, Schlemper BR Jr, Caponi S. 50th anniversary of the declaration of Helsinki: the double standard was introduced. Arch Med Res. 2014;45:600–1.CrossRef
26.
go back to reference Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ. Review article: impact of exercise on physical frailty in patients with chronic liver disease. Aliment Pharmacol Ther. 2019;50:988–1000.CrossRef Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ. Review article: impact of exercise on physical frailty in patients with chronic liver disease. Aliment Pharmacol Ther. 2019;50:988–1000.CrossRef
27.
go back to reference Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479:672–86.CrossRef Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479:672–86.CrossRef
28.
go back to reference Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang F-S, et al. In vivo consequences of liver-specific Interleukin-22 expression in mice: implications for human liver disease progression. Hepatology. 2011;54:252–61.CrossRef Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang F-S, et al. In vivo consequences of liver-specific Interleukin-22 expression in mice: implications for human liver disease progression. Hepatology. 2011;54:252–61.CrossRef
29.
go back to reference Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88.CrossRef Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88.CrossRef
30.
go back to reference Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee J-S, Kim JH, Greten TF, Wang XW. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology. 2015;62:481–95.CrossRef Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee J-S, Kim JH, Greten TF, Wang XW. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology. 2015;62:481–95.CrossRef
31.
go back to reference Fan YC, Zhang YY, Wang N, Sun YY, Wang K. Tumor necrosis factor-alpha-induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B. Oncotarget. 2017;8:30781–92.PubMedPubMedCentral Fan YC, Zhang YY, Wang N, Sun YY, Wang K. Tumor necrosis factor-alpha-induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B. Oncotarget. 2017;8:30781–92.PubMedPubMedCentral
32.
go back to reference Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146:1193–207.CrossRef Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146:1193–207.CrossRef
33.
go back to reference Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, Meregaglia D, Nicolini A, Lubatti L, Riggio O. MELD score is better than child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494–500.CrossRef Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, Meregaglia D, Nicolini A, Lubatti L, Riggio O. MELD score is better than child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494–500.CrossRef
34.
go back to reference Qin B, Wei T, Wang L, Ma N, Tang Q, Liang Y, Yang Z, Zhou L, Zhong R. Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to toll-like receptor ligands in primary biliary cirrhosis. J Gastroenterol Hepatol. 2016;31:1177–83.CrossRef Qin B, Wei T, Wang L, Ma N, Tang Q, Liang Y, Yang Z, Zhou L, Zhong R. Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to toll-like receptor ligands in primary biliary cirrhosis. J Gastroenterol Hepatol. 2016;31:1177–83.CrossRef
35.
go back to reference Xu DD, Li XF, Li YH, Liu YH, Huang C, Meng XM, Li J. TIPE2 attenuates liver fibrosis by reversing the activated hepatic stellate cells. Biochem Biophys Res Commun. 2018;498:199–206.CrossRef Xu DD, Li XF, Li YH, Liu YH, Huang C, Meng XM, Li J. TIPE2 attenuates liver fibrosis by reversing the activated hepatic stellate cells. Biochem Biophys Res Commun. 2018;498:199–206.CrossRef
36.
go back to reference Sherman M. Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis. Semin Liver Dis. 2010;30:3–16.CrossRef Sherman M. Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis. Semin Liver Dis. 2010;30:3–16.CrossRef
37.
go back to reference Padmavathi G, Banik K, Monisha J, Bordoloi D, Shabnam B, Arfuso F, Sethi G, Fan L, Kunnumakkara AB. Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: functions and downstream targets involved in cancer progression. Cancer Lett. 2018;432:260–71.CrossRef Padmavathi G, Banik K, Monisha J, Bordoloi D, Shabnam B, Arfuso F, Sethi G, Fan L, Kunnumakkara AB. Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: functions and downstream targets involved in cancer progression. Cancer Lett. 2018;432:260–71.CrossRef
38.
go back to reference Niture S, Dong X, Arthur E, Chimeh U, Niture SS, Zheng W, Kumar D. Oncogenic role of tumor necrosis factor alpha-induced protein 8 (TNFAIP8). Cells. 2018;8:9.CrossRef Niture S, Dong X, Arthur E, Chimeh U, Niture SS, Zheng W, Kumar D. Oncogenic role of tumor necrosis factor alpha-induced protein 8 (TNFAIP8). Cells. 2018;8:9.CrossRef
39.
go back to reference Wang L, Chen C, Feng S, Tian J. TIPE2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3kinase/AKT signaling pathway. Mol Med Rep. 2018;17:7017–26.PubMedPubMedCentral Wang L, Chen C, Feng S, Tian J. TIPE2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3kinase/AKT signaling pathway. Mol Med Rep. 2018;17:7017–26.PubMedPubMedCentral
40.
go back to reference Zhang YH, Yan HQ, Wang F, Wang YY, Jiang YN, Wang YN, Gao FG. TIPE2 inhibits TNF-alpha-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-kappaB activation. Int J Oncol. 2015;46:254–64.CrossRef Zhang YH, Yan HQ, Wang F, Wang YY, Jiang YN, Wang YN, Gao FG. TIPE2 inhibits TNF-alpha-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-kappaB activation. Int J Oncol. 2015;46:254–64.CrossRef
Metadata
Title
Tumor necrosis factor-α-induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection
Authors
Yi Liu
Jia Jin
Jian Ji
Xi-Mei Gao
Yu-Chen Fan
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2019
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-019-1224-7

Other articles of this Issue 1/2019

Virology Journal 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.